{
    "clinical_study": {
        "@rank": "95916", 
        "arm_group": [
            {
                "arm_group_label": "oxytocin", 
                "arm_group_type": "Experimental", 
                "description": "oxytocin 100 micrograms administered intrathecally (IT)"
            }, 
            {
                "arm_group_label": "normal saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "preservative free normal saline: 3 milliliters administered intrathecally (IT)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine the effect of oxytocin given into the spinal fluid\n      on pain and areas and intensity of hyperalgesia and allodynia in patients with chronic\n      neuropathic pain."
        }, 
        "brief_title": "Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Neuropathic Pain", 
        "condition_browse": {
            "mesh_term": "Neuralgia"
        }, 
        "detailed_description": {
            "textblock": "Rationale: The investigators anticipate that oxytocin will be effective after spinal\n      injection in humans to acutely relieve chronic neuropathic pain.\n\n      Objectives: Determine the effect of intrathecal oxytocin on pain and areas and intensity of\n      hyperalgesia and allodynia in patients with chronic neuropathic pain.\n\n      Interventions: A computer generated randomization will be used to determine the group for\n      each subject. Subjects will be randomized to receive an intrathecal injection of saline\n      (placebo) or oxytocin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Weight < or equal to 240 pounds\n\n          -  Neuropathic pain for > 6 months: with primary pain area below the umbilicus\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity, allergy, or significant reaction to any ingredient of the study\n              drug or  lidocaine\n\n          -  Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of\n             the Principal Investigator, would place the subject at increased risk (active\n             gynecologic disease in which increased tone would be detrimental e.g., uterine\n             fibroids with ongoing bleeding), compromise the subject's compliance with study\n             procedures, or compromise the quality of the data\n\n          -  Pregnancy\n\n          -  spinal cord stimulators, chronic intrathecal drug therapy, or oral opioid treatment\n             for > 3 months at a current dose of > 100 milligram (mg) morphine per day or\n             equivalent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100956", 
            "org_study_id": "00027272"
        }, 
        "intervention": [
            {
                "arm_group_label": "oxytocin", 
                "description": "oxytocin 100 micrograms administered intrathecally (IT)", 
                "intervention_name": "oxytocin 100 micrograms", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "normal saline", 
                "description": "Normal Saline (preservative free) administered intrathecally (IT)", 
                "intervention_name": "Normal Saline (preservative free)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxytocin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "chronic pain", 
            "neuropathic pain"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Winston Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157"
                }, 
                "name": "Wake Forest School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain", 
        "overall_contact": {
            "email": "recurry@wakehealth.edu", 
            "last_name": "Regina Curry, R.N.", 
            "phone": "336-716-4294"
        }, 
        "overall_official": {
            "affiliation": "Wake Forest School of Medicine", 
            "last_name": "James C. Eisenach, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pain will be measured by visual analog scale", 
            "measure": "Pain", 
            "safety_issue": "No", 
            "time_frame": "60 minutes post injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100956"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wake Forest School of Medicine", 
            "investigator_full_name": "James C. Eisenach, M.D.", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Wake Forest School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "James C. Eisenach, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}